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Abstract.  Platelet-derived growth factor is a potent 
mitogen for cells of mesenchymal origin. It is made 
up of two polypeptide chains (A and B) combined in 
three disulfide-linked dimeric forms (AA, AB, and 
BB).  Here, the biosynthesis and proteolytic processing 
of the two homodimeric forms of PDGF (AA and BB) 
were studied in CHO cells stably transfected with 
A-chain (short splice version) or B-chain eDNA. 
PDGF-AA was processed to a 30-kD molecule which 
was secreted from the cells. In contrast, PDGF-BB 
formed two structurally distinct end products; a minor 
secreted 30-kD form and a major cell-associated 24- 
kD form. Immunocytochemical studies at light- and 
electron-microscopical levels revealed presence of 
PDGF in the Golgi complex, in lysosomes, and to a 
smaller extent in the ER. From analysis of cells treated 
with brefeldin A, an inhibitor of ER to Golgi trans- 
port, it was concluded that dimerization occurs in the 
ER, whereas the proteolytic processing of PDGF-AA 
and PDGF-BB precursors normally occurs in a com- 
partment distal to the ER. Exposure of the cultures to 
the lysosomal inhibitor chloroquine led to an increased 
cellular accumulation of PDGF-BB, as determined both 
by metabolic labeling experiments and immunocyto- 
chemical methods, indicating that the retained form of 
PDGF-BB is normally degraded in lysosomes. Struc- 
tural analysis of the two end products of PDGF-BB re- 
vealed that the secreted 30-kD form is a dimer of pep- 
tides processed as the B-chain of PDGF purified from 
human platelets, and that the retained 24-kD form 
is made up of subunits additionally processed in the 
NH2-terminus. Also, the 24-kD form was shown to be 
composed of proteolytic fragments held together by di- 
sulfide bridges. Taken together these findings suggest 
that the newly synthesized PDGF A- and B-chains are 
dimerized in the ER and thereafter transferred to the 
Golgi complex for proteolytic processing. From there, 
PDGF-AA is carried in vesicles to the cell surface for 
release extracellularly by exoeytosis. A  smaller part 
of PDGF-BB (the 30-kD form) is handled in a similar 
way, whereas the major part (the 24-kD form) is gen- 
erated by additional proteolysis in the Golgi complex, 
from which it is slowly carried over to lysosomes for 
degradation. 
p 
LATELET-derived  growth factor is a powerful mitogen 
for cells of  mesenchymal  and glial origin and has been 
implicated in the regulation of cell proliferation  dur- 
ing normal as well as pathological  conditions  (Heldin and 
Westermark, 1990; Raines et al., 1990). It is composed of 
two polypeptide chains, A and 13, that give rise to three disul- 
fide-linked dimers, AA, AB, and BB. The A-chain and the 
B-chain  are encoded by  separate  but related genes,  the 
B-chain gene being identic~ to the protooncogene  c-sis. The 
A-chain occurs in two variants that arise by differential splic- 
ing. The longer variant differs from the more common short- 
er variant by an 18-amino acid long COOH-terminal exten- 
sion. The different isoforms of PDGF exert their effects on 
target cells by interaction with high affinity receptors of two 
types, the o~ receptor which binds either the A-chain or the 
B-chain,  and the/3 receptor which binds only the B-chain 
(Westermark et al., 1989; Heldin and Westermark, 1990). 
Both  the  PDGF  B-chain  and  the  short variant  of the 
A-chain contain hydrophobic leader sequences and are syn- 
thesized as precursor molecules of 241 and 196 amino acids, 
respectively. Studies on cells transfected with eDNA encod- 
ing the PDGF B-chain and/or the short splice version of the 
A-chain have indicated that PDGF-AA and PDGF-AB are 
trimmed proteolytically after dimerization and secreted as 
30-kD products, whereas PDGF-BB is processed into a mi- 
nor secreted product of 30 kD and a major cell-associated 
product of 24 kD (Robbins et al.,  1983; Beckmarm et al., 
1988; Bywater et ai., 1988; 0stman et al., 1988). Electron 
microscopic and cytochemical studies of transfected CHO 
cells have revealed that only small amounts of PDGF-AA are 
present intracellularly,  mainly in the ER and in secretory 
vacuoles.  On the other hand, PDGF-BB occurs in diluted 
form in the ER, is highly concentrated  in the Golgi complex, 
and is at least in part transferred to the lysosomes (Thyberg 
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and of peptides derived from hmnan platelet PDGF-AB have 
shown that the B-chain of the 30-kD PDGF forms consists 
of amino acids 82-190 of the precursor and thus represents 
a form that is both NH2- and COOH-terminally  trimmed 
(Johnsson et al.,  1984). In contrast, the A-chain appears to 
be cleaved only NH2 terminally. 
Analysis of chimeras between the short splice version of 
the PDGF A-chain and the B-chain has recently localized the 
structural determinant for cellular retention of PDGF-BB to 
amino acids 219-229 within the COOH-terminal propart., of 
the PDGF B-chain precursor (LaRochelle et aL, 1991; Ost- 
man et al., I99I). Interestingly, this sequence is homologous 
to the unique COOH-terminal  sequence of the long splice 
version of the PDGF A-chain, as well as to a sequence wit~hin 
the longer variant of VEGF/VPF, a recently  identified  en- 
dothelial call growth factor CKeck et al., 1989; Leung et al., 
1989). Analysis of the processing of the long splice version 
of the A-chain, transiently expressed in COS cells, also re- 
vealed a p..rocessing pattern very shnilar to that of the PDGF 
B-chain (Ostman et al.,  1991).  However, the detailed func- 
tional and structural properties,  as well as the intracellular 
fate of the retained forms, remain unknown. 
Here, the processing of PDGF-A_A  and PDGF-BB were ex- 
plored  in  further  detail.  Processing  intermediates  were 
identified by pulse-chase analysis  and their subceUular lo- 
calization determined by immunofluorescence and immuno- 
electron microscopy. Cells treated with brefeldin A, a fungal 
metabolite that has been found to inhibit ER to Golgi trans- 
port,  carbohydrate  trimming  and  proteolytic  cleavage  of 
secretory proteins (Klansner et al., 1992), was used to iden- 
tify the subcellular localization of the proteolytic processing 
of the precursor forms of PDGF-AA and PDGF-BB. The role 
of the lysosomes in the degradation of PDGF-BB retained in- 
tracellularly  was determined  by  studying cultures treated 
with ehloroquine, a weak base that raises intralysosomal pH 
and  inhibits  lysosomal  degradation  of organic  molecules 
(Mellman et al., 1986). Finally, the two different PDGF-BB 
end products were structurally characterized and compared. 
Materials and Methods 
Transfected Cell Lines 
ClIO (dhfr-) cells (DxB11) were eotransfe,.~ed  with the plasmid pAd (Chiron 
Corporation,  Emeryville, CA),  which  contains  the mouse dihydrofolate 
reductase gene under control of the adenovims  major late promoter,  and 
either the pSV7d-PDGF-AI02 or the pSV7d-PDGF-B1 plasmids (Ostman et 
al., 1988), which encode the shorter variant of the human PDGF A-chain 
and the human PDGF B-chain,  respectively. Transfection,  selection,  and 
isolation of the cell lines CHO-PDGF-A and CHO--PDGF-B (c-sis45), 
which expressed high levels of PDGF-AA and PDGF-BB, respectively, were 
made as described  (~)stman et al., 1988). 
Construction, Expression, and 
Analysis of  PDGF  Mutants PDGFB-R11~ and 
PDGFB-RIOK 109, 113A 
Site-directed mutagenesis was performed by the method of Kunkel et al. 
(1987). BgllI/EcoRI  fragments in which Arg-113 was mutated to an alanine 
residue (PDGFB-Rll3A) or in which Arg-108, -109, and -113 were mutated 
to alanine residues (PDGFB-R108, 109, l13A) were inserted into the vector 
pSV7d/PDGF-B1 (Ostman  et aL,  1989), from which the corresponding 
wild-type sequence had been excised. Transfeetions of  COS cells and anaty- 
sis of transiently expressed proteins were performed as described (Ostman 
et al., 1991). 
Drugs and Immunological Reagents 
Brefeldin A (Epicentre Technologies, Madison, WI) was used at a final con- 
centration of 10 ttM (diluted from a 4D mM stock solution in ethanol) and 
chloroquine at 100 ~,M (diluted from a 5.0 mM stock solution in medium 
F-12). The antisera against human platelet PDGF and recombinant PDGF- 
A.A and PDGF-BB have been described  previously  (Heldin et al., 1981; 
Tbyberg et al.,  1990). A mouse mAb against a synthetic fragment of the 
PDGF B-chain (Shiraishi et al.,  1989) was kindly provided by Moehida 
Pharmaceutical  Company  (Tokyo, Japan)  and  rabbit  antibodies  against 
mannosidase H (Moremen et al., 1991) by Dr. K. W. Moremen (University 
of  Georgia,  Athens,  GA) and  Dr.  M. G. Farquhar  (University  of  California 
San Diego,  La Jolla,  CA). Rhodamine- and fluorescein-conjugated  swine 
immunoglobulins to rabbit  immunoglobulins were obtained  from Dako 
Corp.  (Glostrup,  Denmark), rhodaminc-conjugated  goat  immunoglobniins 
to  mouse  immunoglobulins  from  Sigma  Chemical Co. (St.  Louis,  MO), and 
peroxidase-conjugated,  affinity-purified  F(ab')2  fragments  of goat anti- 
rabbit  IgG from Immunotech (MarseiUe,  France). 
Immunoprecipitation of  Metabolically Labeled 
CHO-PDGF-A and CHO-PDGF-B Cells 
Cells grown to confluence in 25-cm  2 plastic flasks were labeled with 0.3 
mCi [35S]eysteine in 1.5 ml cysteine-free medium supplemented with 10% 
dialyzed FCS, washed with cysteine-free medium,  and chased in medium 
containing 250/~g/ml unlabeled cysteine. Chase medium and cell lysates 
were  subjected  to  immunoprecipitation  with  anti-PDGF-AA or  anti- 
PDGF-BB and the precipitates were analyzed by SDS-PAGE and fluorogra- 
phy as described  (Ostman et al,  1988). 
Cyanogen Bromide Cleavage of  l~S]Cysteine.labeled 
and Immunoprec(tTitated PDGF-BB 
CHO-PDGF-B cells were labeled with [35S]cysteine for 3 h and chased in 
nonradioactive medium for 2 h as described above; cell lysates and condi- 
tioned media were then collected and immunoprecipitated  using a PDGF 
antiserum  (Heldin et al., 1981), The precipitated  material was incubated 
with 100/A 50% protein A-Sepharose slurry in PBS, pH 7.3, washed, and 
collected by centrifugation.  Formic acid was added to the samples, either 
alone (final concentration  70%, total vol 300 ~1) or together with CNBr 
(final  concentration  I0  mg/ml).  The  protein  A-Sepharose  beads  were 
pelleted by centrifugation and the supernatants were incubated for 24 h at 
20~  The samples were dried in a SpeedVac concentrator, dissolved in 200 
/~l SDS-sample buffer (Blobel and Dobberstein,  1975) without reducing 
agent, and heated to 95~  for 3 rain. A 100-t~l aliquot of each sample was 
reduced by incubation in 10 mM DTT for 90 s at 950C and alkylated by 
addition of iodoacetamide to a final concentration of 50 mM and continued 
incubation at 20oC for 15 rain. The samples were finally analyzed by SDS- 
PAGE and fluorography (Ostman et al., 1988). 
Immunofluorescence Microscopy 
For indirect  immunofluorescence  microscopy,  cells  grown on glass  cover- 
slips  were fixed  in  2% formaldehyde  in  PBS, pH 7.3,  for  30  rain  at  20oc, 
quenched in 50 told  NH4CI in PBS (15 min),  permeabilized  with  0.05  % 
Triton X-100 in PBS O0 rain), exposed to primary and secondary antibodies 
(2-3 h each) in PBS/0,1% BSA, and finally mounted in 90% glycerol con- 
taining  0.1% p-phenylenedlamine.  The specimens  were examined  in a 
Nikon Labophot  microscope 0Nikon Inc., Melville, NY) with epifluores- 
cence optics Cl~ri-X  pan film; Eastman Kodak Co., Rochester, NY). In the 
double staining experiments the ceils were fixed in acetone/methanol  (1/1 
by vol) for 5 rain at 20~  and thereafter  rinsed twice in PBS. Otherwise, 
the procedure  was the same as described  above. 
Immunoelectron Microscopy 
Immunoperoxidase staining was performed  as described  (Brown and Far- 
quhar, 1989; Tbybcrg et al., 1990). Shortly, the cells were fixed in phos- 
phate-buffered 2 % formaldehyde/O.05% glutaraldehyde  (60 rain),  rinsed 
with PBSI0.1% BSA, and permeabilized with 0.05% saponin in PBS/0.1% 
BSA (5 rain).  They were exposed to primary antibodies and peroxidase- 
conjugated  goat  anti-rabbit  F(ab')2  in  PBSt0.1%  BSAI0.05% saponin 
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cells were fixed in 3 % buffered glutaraldehyde (30 rain) and rinsed again 
with PBS. Peroxidase activity was visualized by incubation with 0.5 mg/ml 
DAB tetra-HCl (Sigma Chemical Co.) plus 0.01% H202 in PBS (10-20 
min).  The cells were then scraped  off the petri dishes in 0.1 M sodium 
r  buffer, pH 7.3, and transferred to plastic tubes, postfixed 
in 1% osmium tetroxide  in 0.1 M sodium cacodylate-HCl  buffer, pH 7.3, 
containing 0.5 % potassium ferrocyanate (60 min at 4aC), dehydrated in eth- 
anol,  stained  with 2% uranyl  acetate  in ethanol,  and embedded  in low- 
viscosity epoxy resin. Thin sections were cut on an LKB Ultratome IV and 
examined in an electron microscope (model 100CX; Jeol U. S. A. Inc., Pea- 
body, MA) at 60 IN (Kodak 4489 film; Eastman Kodak Co.). 
Results 
Processing and Subcellular Localization of  PDGF-AA 
and PDGF-BB in Transfected Cells 
To study the processing  and assembly  of PDGF-AA and 
PDGF-BB, metabolic labeling and immunoprecipitation ex- 
periments  were performed on two transfected  CHO cell 
lines, CHO-PDGF-A and CHO-PDGF-B.  These cell lines 
were obtained by cotransfecting an expression vector con- 
taining the coding region of the shorter variant of the human 
PDGF A-chain and the PDGF B-chain, respectively, with an 
expression vector containing the mouse dihydrofolate reduc- 
tase (dhfr) cDNA into CHO (dhfr-) cells. After a 2 h pulse 
with [3~S]cysteine, the ceils were chased for various periods 
of time in medium containing  an excess of unlabeled cys- 
teine.  The cell lysates and the corresponding  media were 
then subjected  to immunoprecipitation  with rabbit  PDGF 
antisera and the immunoprecipitates were analyzed by SDS- 
PAGE and fluorography. 
Unreduced gels of  material precipitated from the medium 
showed that already at the end of the radioactive pulse, the 
major part of PDGF-AA was secreted as species of 40, 35, 
and 30 kD (Fig. 1, B and E); during the subsequent chase, 
the larger forms in the medium were converted into the 30- 
kD form. All these three forms, as well as a 23-kD form, 
were also present in the cell lysate (Fig. 1 B). The latter spe- 
cies was seen only at the earliest time point studied and most 
likely represents an undimerized precursor  form,  since re- 
duced gels of the cell lysates of the earliest time point re- 
vealed a major band of  23 kD and a doublet of 16-17 kD (Fig. 
1,4). On the basis of these observations, it is concluded that 
the 40-kD  form corresponds  to a dimer composed  of un- 
cleared 23-kD PDGF A-chain precursors,  whereas the 30- 
kD form is a dimer of processed  16-17-kD chains. The 35- 
kD form most likely represents an intermediate where only 
one of the subunits is processed. 
In the case of PDGF-BB, unreduced gels showed an initial 
56-kD dimeric form in the cell lysate, which via an inter- 
mediate of 40 kD, was converted into a final product of 24 
kD (Fig. 1 I). When the gels were run under reducing condi- 
tions, monomeric forms of 28, 22, and 12 kD were found 
(Fig.  1 H). Under the exposure conditions used in the ex- 
periment illustrated in Fig.  I, no secreted forms of PDGF- 
BB were observed. However, films exposed for longer times 
revealed  in the medium at the earliest time points  small 
amounts of  dimeric species with sizes between 56 and 40 kD 
in addition  to a 30-kD  form; as the chase continued,  the 
higher molecular weight species disappeared and the 30-kD 
form accumulated (data  not shown).  Comparisons  of au- 
toradiograms exposed an equally long time revealed that the 
24-kD form of PDGF-BB was at least 10-fold as abundant 
as the secreted 30-kD form. Thus, the product of the trans- 
fected PDGF B-chain cDNA is also dimerized before pro- 
teolysis and forms a 56-kD precursor,  which via an inter- 
mediate of 40 kD, is processed into two final forms, a major 
cell-associated form of 24 kD and a minor secreted form of 
30 kD. 
The intracellular localization of PDGF-AA and PDGF-BB 
in the transfected cells was studied by indirect immunofluo- 
rescence  microscopy  and  immunoperoxidase  staining  in 
combination with EM. CHO-PDGF-A cells showed a weak 
juxtanuclear reactivity with anti-PDGF-AA  in the fluores- 
cence microscope  (Fig. 2 A). With the immunoperoxidase 
method, only  little reactivity  for PDGF-AA could  be detected 
in these cells (see Thyberg et al., 1990). In CHO-PDGF-B 
cells a juxtanuclear staining of somewhat variable extension 
was demonstrated with anti-PDGF-BB  by fluorescence mi- 
croscopy (Fig. 2 C). At the electron microscopic level, reac- 
tion product was most prominent in stacked Golgi cisternae 
(Fig. 3 A). However, there was also a positive staining of 
lysosome-like  vacuoles  and,  more  occasionally,  a  weak 
staining of  the ER (see Thyberg et al., 1990). With antibod- 
ies against mannosidase  II,  an established  marker of the 
Golgi complex (Novikoff et al., 1983; Moremen and Tous- 
ter,  1988), the staining was more clearly restricted  to the 
stacked Golgi cisternae (Fig. 3 B). Double immunofluores- 
cence microscopy with the monoclonal PDGF B-chain anti- 
body and anti-mannosidase H confirmed that PDGF-BB was 
present not only within but also outside the Golgi complex, 
namely in numerous vesicles presumably representing endo- 
somes and/or lysosomes (Fig. 2, E and F). 
Effects of  Brefeidin A on Processing, Turnover, and 
Localization of  PDGF-AA and PDGF-BB 
To identify the subcellular compartment  where the proteo- 
lyric processing of  PDGF-AA and PDGF-BB takes place, the 
transfected cells were treated with brefeldin A and subjected 
to pulse--chase  analysis as described above. In CHO-PDGF-A 
cells, brefeldin A was found to strongly inhibit the proteo- 
lyric processing of PDGF-AA and totally block its secretion 
into the medium (Fig. 1, C and F). In CHO-PDGF-B ceils, 
brefeldin A slowed down the conversion of  the precursor into 
smaller  forms (Fig.  1 J). The 40-kD  form, which in un- 
treated cells was the predominant  form after 2 h of chase 
(Fig. 1 I), was detected in the brefeldin A-treated cells only 
after 8 h of chase (Fig. 1 J). In the brefeldin A-treated cells, 
the major component was initiaLly  56 kD, like the precursor 
of  untreated ceils. However, with time this species increased 
in size, most likely because of  posttranslational modifications. 
Thus,  brefeldin A did not affect the dimerization  of the 
newly synthesized PDGF A- and B-chains but markedly in- 
terfered with the proteolytic processing of  PDGF-AA as well 
as PDGF-BB. We therefore conclude that dimerization oc- 
curs already in the ER, whereas the proteolytic processing 
takes place in compartments distal to the block induced by 
brefeldin A. Since in untreated cultures precursor and ma- 
ture forms of PDGF-AA were found both in the cells and in 
the medium, it seems likely that the processing in this case 
may take place either in the Golgi complex or later on along 
the secretory pathway,  i.e., in secretory vacuoles or extracel- 
lularly. With regard to PDGF-BB, the proteolytic processing 
seems more restricted to the Golgi complex. 
OsUnan et al. Biosynthesis of PDGF-AA and PDGF-BB  511 Figure 1. Pulse-chase  analysis  of  the  processing  of  PDGF-AA and PDGF-BB in  untreated  metabolically  labeled  cells  and cells  treated 
with 10  ~M brefeldin  A or I00 #M chloroquine.  CHO-PDGF-A  and CHO-PDGF-B  cells  were labeled  for  2 h with [3sS]cysteine  and 
then  grown  for  the  indicated  time  periods  in  medium containing  an  excess  of  unlabeled  cysteine.  Cell  lysates  and  conditioned  media  were 
subjected  to  immunoprecipitation  using  anti-PDGF-AA or  anti-PDGF-BB and  the  precipitates  were  analyzed  by  SDS-PAGE under  nonre- 
ducing  (B-G  and  I-N) conditions  followed  by  fluorography.  A and  H show  the  result  of  SDS-PAGE under  reducing  conditions  of  the  samples 
shown in  B and  L respectively.  Positions  of  molecular  weight  markers are  indicated  between A and B and H  and L 
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microscopy of CHOoPDGF- 
A cells (.4 and B) and CHO- 
PDGF-B cells (C-F) kept in 
normal medium (A, (7, E, and 
F) or treated with 10/~M bre- 
feldin A for 30 (B) or 120 (/9) 
rain. Single staining with rab- 
bit anti-PDGF-AA (A and B) 
or anti-PDGF-BB (C and D), 
or double staining with mouse 
anti-PDGF  B-chain (E) and 
rabbit anti-marmosidase  II (F). 
Bars, 20/~m. 
To localize the PDGF forms in cells treated with brefeldin 
A, CHO-PDGF-A and CHO-PDGF-B cells were stained for 
indirect immunofluorescence microscopy. After treatment 
with 10/~M brefeldin A for 30 or 120 rain, the staining of 
CHO-PDGF-A cells was spread throughout  large parts of  the 
cells, often showing a reticular pattern (Fig. 2 B). If the cells 
were exposed to the drug for 120 rain, rinsed, and then in- 
cubated in drug-free medium for 60 rain, the staining pattern 
was normalized. Treatment of CHO-PDGF-B cells with 10 
/~M brefeldin A  turned the Golgi-like staining into a dis- 
persed ER-like pattern. The changes were evident after 30 
rain and fully  developed after 120 rain of  drug exposure (Fig. 
2 D). Upon removal of brefeldin A, a juxtanuclear distribu- 
tion of the reaction product was reestablished. 
Brefeldin A-treated  cells were  also studied by EM.  In 
CHO-PDGF-A cells, treatment with 10 ~M brefeldin A for 
120 rain gave rise to a weak staining in the ER in part of the 
cells (not shown). Treatment of  CHO-PDGF-B cells with 10 
/~M brefeldin A led to distinct changes, including a promi- 
nent increase in overall reactivity with anti-PDGF-BB and 
a redistribution of reactive material from the Golgi complex 
to the ER. After 30 rain of exposure to the drug, the Golgi 
stacks were to a large extent disintegrated into vesicular and 
tubular elements and reaction product for PDGF-BB oc- 
curred in some of these elements as well as in ER cisternae 
(Fig. 4 A). After 120 rain, no recognizable Golgi stacks were 
noted and the vesiculotubular structures remaining in the 
former Golgi area were negative for PDGF-BB (Fig. 4 B). 
On the other hand, large amounts of reaction product was 
found in ER cisternae throughout the cytoplasm, including 
the nuclear envelope (Fig. 4  C). 
Chloroquine Causes Accumulation of 24-kD 
PDGF-BB in Lysosomes 
Our previous studies have indicated that PGDF-BB is re- 
tained intraceUularly and is at least in part transferred to 
lysosomes (Thyberg et al., 1990).  To investigate if these or- 
ganelles represent the normal site of degradation of the pro- 
tein, the cultures were treated with the weak base chloro- 
quine, a well established inhibitor of lysosomal proteolysis 
(Mellman et al.,  1986).  In pulse-chase experiments with 
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localization  of PDGF-BB  (A) 
and  mannosidase  11 (B)  in 
CHO-PDGF-B  cells  kept in 
normal  medium.  Reaction 
product is  observed in  stacked 
Golgi cistcrnae  (G). ER, en- 
doplasmic reticulum; N, nu- 
cleus. Bars, 0.5 gm. 
Figure  4.  Immunoperoxidase 
localization  of PDGF-BB  in 
CHO-PDGF-B cells exposed 
to  l0 gM brefeldin A for 30 
(A) or 120 (B and C) min. Af- 
ter 30 min, staining  for PDGF- 
BB appears in the ER and in a 
few tubulovesicular  structures 
(V) in the former Golgi area 
(A). After 120 rain,  most of 
the latter structures  are nega- 
tive (B),  whereas  a  positive 
reaction is  found throughout 
large parts of the ER (C). N, 
nucleus.  Bars,  0.5 gin. 
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quine  on  the  distribution  of 
PDGF-BB  in CHO-PDGF-B 
cells as  studied  by light  mi- 
croscopy (A and B) and EM 
(C). Control cultures (,4) and 
cultures  exposed  to  100 #M 
chloroquine  for 15 h  (B and 
C) were fixed and stained for 
PDGF-BB using the immuno- 
peroxidase  technique.  At the 
electron microscopic level (C), 
reaction  product is  found  in 
swollen lysosomes (L) with in- 
clusions  of variable  appear- 
ance. Bars: (.4 and B) 20 #m; 
(C) 0.5 ~m. 
metabolically  labeled  CHO-PDGF-B  cells,  chloroquine 
slowed down the disappearance of labeled forms as com- 
pared with untreated cells (Fig.  1, I  and K).  However, the 
pattern of processing was not changed,  suggesting that the 
proteolytic steps leading to formation of the 40- and 24-kD 
forms occurred in compartments insensitive to chloroquine. 
Furthermore,  the  amount  of PDGF-BB  secreted  into  the 
medium was unaffected by chloroquine,  as determined by 
Figure  6.  CNBr  cleavage of 
PDGF-BB. PDGF-BB immu- 
noprecipitated from metaboli- 
cally labeled  CHO-PDGF-B 
cells, or the corresponding con- 
ditioned medium, was treated 
with 70% formic acid alone or 
70%  formic acid  containing 
10 mg/ml CNBr. The samples 
were analyzed by SDS-PAGE 
under nonreducing  or reduc- 
ing  conditions,  followed  by 
fluorography. Arrowheads in- 
dicate  the different  forms of 
PDGF-BB and their apparent 
sizes expressed in kilodaltons. 
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PDGF-A cells, no distinct effects on the assembly, process- 
ing,  and secretion of PDGF-AA were detected after treat- 
ment with ehloroquine (Fig.  I, D and G). 
Immunocytochemical analysis of CHO-PDGF-B cells ex- 
posed to chloroquine for 4-24 h revealed a gradual accumu- 
lation  of vacuoles filled with PDGF-BB (Fig.  5, A and B). 
In the electron microscope, these vacuoles were identified as 
lysosomes filled with inclusions of incompletely degraded 
material (Fig. 5 C). In CHO-PDGF-A cells, no intracellular 
accumulation of PDGF-AA could be detected after ehloro- 
quine treatment. 
Structural Differences Between the 24- and 30-kD 
Forms of PDGF-BB 
The finding of two structurally different dimeric end prod- 
ucts of  PDGF-BB prompted us to compare them structurally. 
Using a procedure developed for the purification  of PDGF- 
AA secreted from a human osteosarcoma cell line (Heldin 
et al., 1986), the secreted form was purified from serum-free 
conditioned media. By NH2-terminal  amino acid sequenc- 
ing the secreted PDGF-BB was found to display the same 
NH2-terminus  as the B-chain of platelet PDGF-AB,  i.e., 
starting  at position 82 of the precursor molecule (data not 
shown).  Wnen analyzed by SDS-PAGE,  the secreted form 
also appeared very similar to recombinant PDGF-BB pro- 
duced in yeast (Ostman et al., 1989), which is composed of 
subunits containing amino acids 82-190 of  the PDGF B-chain 
precursor (data not shown). Hence, we conclude that the 30- 
kD form is a dimer composed of two subunits processed as 
the B-chain in human platelet PDGF-AB. This form of se- 
creted PDGF-BB has also been identh~ied as one of  the PDGF 
isoforms present in the conditioned media of CHO cells sta- 
bly expressing both the PDGF B-chain and the short splice 
version of the A-chain  (Ostman et al.,  1988). 
To elucidate the structure oftbe 24-kD form relative to the 
30-kD form, the various forms of PDGF-BB were subjected 
to CNBr cleavage, the rationale being that only forms retain- 
ing any of the methionine residues in the PDGF B-chain 
precursor (amino acids 64 and 93) would shift in size after 
cleavage.  CHO-PDGF-B cells were metabolically labeled 
with  [3sS]cysteine; the medium and cell lysate were then 
subjected to immunoprecipitations.  The samples were split 
in two parts and treated either with CNBr in 70%  formic 
acid or 70% formic acid only, and then analyzed by SDS- 
PAGE and fluorography. The 56-, 40-, 30-, and 24-kD forms 
could be identified  in the immunopreeipitates treated with 
formic acid only (indicated  by arrowheads in Fig.  6);  all 
these species except the 24-kD form shifted in mobility after 
exposure to CNBr (Fig.  6).  This  suggests  that the 24-kD 
form, in contrast to the 30-kD form, lacks the methionine 
at position 93. Analysis of the CNBr-treated samples under 
reducing  conditions  gave results  consistent  with  this  in- 
terpretation;  only the  12-kD from was resistant to CNBr 
(Fig. 6). In agreement with this finding, it was not possible 
to detect the 24-kD form in immunoprecipitates of cells la- 
beled with [35S]methionine (data not shown). 
Amino acid sequencing of the 30-kD form of PDGF-BB 
has shown that proteolytic processing after the arg!.mne resi- 
due at position 113 occurs with high frequency (Ostman et 
al.,  1988, 1989; Hart et ai.,  1990).  To investigate  whether 
proteolysis at that position is involved in the generation of 
the 24-kD form of PDGF-BB, two variants  of the PDGF 
B-chain eDNA were made by site-directed mutagenesis.  In 
PDGFB-RI13A codon 113 was changed to encode alanine 
Figure Z Expression in COS cells and immu- 
nopreeipitations of wild-type PDGF B-chain 
(Wt) and  the mutants PDGFB-Rll3A and 
PDGFB-R10g,109,113A.  T-~ and mock- 
transfeeted (-) COS cells were metabolically 
labeled with rSS]eysteine  for 4 h and chased 
in medium containing excess unlabeled eys- 
teine for 4 h. Lysates  and conditioned media 
were immunopreeipitated with anti-PDGF- 
BB and analyzed  by SDS-PAGE  under reduc- 
ing and nonredueing conditions. 
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arginine residues 108, 109 and 113 were changed to alanine 
residues. These cDNAs were cloned into the vector pSV7d 
and the encoded proteins were transiently expressed in COS 
cells and analyzed  by immunoprecipitations and SDS-PAGE. 
As  shown  in  Fig.  7,  the  amount and structure  of the 
secreted forms was similar for wild-type and mutated vari- 
ants of PDGF-BB. In all cases a 24-kD cell-associated form 
appeared under nonreducing conditions. A small difference 
in  migration  between  the  wild-type  and  mutated  cell- 
associated 24-kD forms could be observed, most likely be- 
cause  of the  changes  of the  positively charged  arginine 
residues to alanine residues, indicating that the mutated re- 
gion is part of the 24-kD form. In contrast, no difference in 
migration was observed in the reduced 12-kD forms derived 
from the wild-type and mutated variants, indicating that they 
do not contain the mutated region. 
Our data thus suggest that the polypeptide chains of  the 24- 
kD component is additionally processed in the NH~ termi- 
nus and composed of proteolytic fragments held together by 
disulfide bridges (Fig. 8 and see below). 
Discussion 
The assembly, biosynthesis, and processing of PDGF-AA 
and PDGF-BB, as determined in the present study, are sche- 
matically illustrated in Fig. 8. The A-chain (short splice ver- 
sion) and the B-chain precursors of PDGF are both synthe- 
sized and dimerized in the ER to form precursor molecules 
of  40 and 56 kD, respectively. PDGF-AA is then transported 
to the Golgi complex and follows the default pathway for 
secretion. Proteolytic processing of PDGF-AA into the final 
30-kD product takes place in the Golgi complex or further 
on along the secretory route.  Since all forms of dimeric 
PDGF-AA were also seen in the conditioned media we con- 
clude that proteolytic processing of  the precursor form of the 
dimer is not a requirement for secretion. PDGF-BB is like- 
wise carried from the ER to the Golgi complex. Here, a ma- 
jor part is processed to a 24-kD component that accumulates 
in the Golgi cisternae before it is transferred to the lysosomes 
and degraded. 
The identification of the compartment in which the 24-kD 
form of  PDGF-BB is degraded as lysosomes relies on a num- 
ber of observations. PDGF-BB can normally be observed in 
the  lysosomes  of cells  transfected  with  B-chain  cDNA 
(Thyberg et al.,  1990).  Moreover, the weak base chloro- 
quine, an inhibitor of lysosomal proteolysis (Mellman et al., 
1986),  slowed down the disappearance of metabolically la- 
beled PDGF-BB from the cells, without interfering with the 
generation of the 24-kD form of the molecule or the secre- 
tion of  the 30-kD form (Fig. 1 K). At the same time, material 
reactive with anti-PDGF-BB accumulated in vacuoles with 
morphological characteristics of lysosomes (Fig. 5). In con- 
trast, many proteins which fail to fold correctly or to assem- 
ble into the proper oligomeric complexes have been found 
to be retained intracellularly and degraded in a pre-Golgi 
compartment insensitive to chloroquine and other lysosomal 
inhibitors (Hurtley and Helenius, 1989; Klausner and Sitia, 
1990). Since no clear effects of chloroquine were seen on the 
processing of PDGF-AA in cells transfected with A-chain 
cDNA (Fig. 1, D and G), the effect of chloroquine can not 
be attributed to a general decrease in the rate of transfer of 
proteins between subcellular compartments. Furthermore, 
since these cells do not express PDGF receptors (Claesson- 
Welsh et al., 1988) the generation and lysosomal degrada- 
tion of the 24-kD form is not a consequence of receptor- 
mediated uptake. 
PDGF-AA  ,S  PDGF-BB 
23 kD  28 kD 
87  196  82  190 










~1~  24 kD 
secreted  extracellularly  degraded  in lysosomes 
Figure 8.  Schematic illustra- 
tion of the assembly, intracel- 
lular transport, and processing 
of PDGF-AA and PDGF-BB 
in transfected CHO cells. See 
the text for discussion. The in- 
terchain disulfide bridges are 
depicted as determined by An- 
dersson et al.  (1992). Other 
disulfide bonds in PDGF have 
not been determined. Part of 
the processing of the 40-kD 
form of PDGF-BB to the 30- 
kD form may also occur extra- 
cellularly in certain cell types 
(La  Rochelle  et  al.,  1991; 
Raines and Ross, 1992). 
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24-kD form for protein sequencing, the detailed structural 
characteristics of the 24-kD form of PDGF-BB remain un- 
known. However,  our data show that the 24-kD form does 
not contain the methionlne residue at position 93 and is thus 
processed NH2-terminally in a different way compared with 
the 30- and 40-kD form (Fig. 6). Also, the studies on PDGF 
B-chain mutants with arginlne residues changed to alanine 
residues indicate that the conversion from the 30 to the 24- 
kD  form is  not mediated through proteolysis at arginine 
residues 108, 109, or 113 (Fig. 7). Finally, the shift in migra- 
tion in SDS-PAGE observed for the mutated nonreduced 24- 
kD forms, but not for the reduced 12-kD forms, suggest that 
the three argmine residues at position 108, 109, and 113 are 
present in the nonreduced 24-kD components, but not in the 
reduced 12-kD components (Fig. 7). One possible interpre- 
tation of these observations is that the conversion from the 
30- to the 24-kD form involves proteolysis in the NH2-ter- 
minus, as indicated by the absence of Met-93 in the 24-kD 
form, and in addition somewhere between Arg-113 and the 
second cysteine (Cys-124).  The most NH2-terminal  cysteine 
residue (Cys-97) would then be disulfide linked to another 
of the cysteine residues further down in the sequence and 
therefore be present in the nora'educed 24-kD form, but not 
in the reduced 12-kD molecule (Fig. 8). It is not known if 
the COOH termini of  the 24- and the 30-kD form are similar. 
However, this seems likely since the 12-kD reduced form is 
recognized by a peptide antiserum raised against a peptide 
encompassing amino acids 154-170 of  the B-chain precursor 
(Ostman et al., 1988), but not by a peptide antiserum raised 
against the COOH-terminal propart of the precursor (Rob- 
bins et al.,  1983).  It remains to be explained why the un- 
reduced molecule shifts from 30 to 24 kD in SDS-PAGE with 
a minimal loss of molecular mass. It is possible that this is 
because of a conformation-dependent anomalous migration 
in SDS-PAGE. 
It was recently reported that PDGF forms of 35--40 kD 
containing the retention sequence associate with the cell sur- 
face  (La Rochelle et al.,  1991, Raines and Ross,  1992); 
COOH-terminal  proteolysis resulted in  release of 30-kD 
PDGF.  Thus,  at  least  three  forms  of PDGF-BB  can  be 
formed, a 24-kD form retained intracellularly and degraded 
in lysosomes, a 40-kD cell surface-associated form, and a 
secreted 30-kD form. The final ratio of the various forms 
is thus likely to be dependent upon the activity of the differ- 
ent proteases involved in the processing.  The presence of 
structurally different forms which differ in their subeellu- 
lar compartmentalization indicates a complex regulation of 
PDGF-BB biosynthesis and processing. A regulatory role of 
proteases  in  the  formation of secreted  versus  cell-bound 
forms has also been indicated in the biosynthesis of trans- 
membrane growth factors like TGF-o~ and CSF-1 (Pandiella 
and Massague,  1991; Stein and Rettenmeier, 1991). 
The presence of end products of PDGF-BB which differ 
in structure as well as compartmentalization and varies be- 
tween different cell types raises questions concerning the 
functional properties of the two forms. The purified secreted 
form, that appears to be structurally identical to the well- 
characterized recombinant PDGF-BB (0stman et al., 1989), 
is mitogenically active (data not shown).  It is not known 
whether the cell-associated 24-kD form is biologically active 
or if it has different functional properties compared with the 
30-kD form.  Several investigators champion the idea that 
transformation by the sis-product is mediated by an intracel- 
lular  PDGF  receptor  activation  (Keating  and  Williams, 
1988;  Huang and Huang,  1988;  Bejcek et al.,  1989)  and 
there is compelling evidence that the PDGF receptor pro- 
tein-tyrosine kinase is activated in an intracellular compart- 
ment in sis-transformed cells. Since receptor autophosphor- 
ylation occurs already in the ER  (Keating and Williams, 
1988),  it is unlikely that the ligand involved is identical to 
the 24-kD form of PDGF-BB, which appears to be generated 
in the Golgi compartment according to the present study. 
Moreover, it is unlikely that the differences in transforming 
properties of the A- and B-chain of PDGF (Beckmann et al., 
1988; Bywater et al., 1988) are due to differences in com- 
partmentalization since it has recently been shown, by ana- 
lyzing the transforming potential of PDGF A/B-chimeras, 
that high transformation potential correlated with the ability 
to activate both types of PDGF receptors and not with the 
formation of predominantly cell-associated forms (La Ro- 
chelle et al.,  1990). 
Thus, an important first aim for future studies will be to 
determine if the 24-kD form has biological activity, and to 
explore the possibility that it interacts with receptors of  other 
types or in other compartments than the 30-kD form, and 
thus  mediates different signals.  Another goal  for further 
studies will be to characterize the proteases involved in the 
formation of the  intracellular and  secreted  forms and to 
study the regulation of these enzymes. 
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